Baxter(US:BAX)2025-10-30 12:30Q3 2025 Performance Summary - Worldwide sales from continuing operations grew by 5% on a reported basis and 2% on an operational basis[17] - Adjusted earnings per share from continuing operations totaled $069 per diluted share, increasing 41% compared to the prior year period[17] - Q3 2025 global reported sales were $28 billion, a 2% operational growth[21] - Adjusted diluted EPS was $069, a 41% increase[21] - Adjusted gross margin was 394%, a decrease of 430 bps[26] - Adjusted operating margin was 149%, an increase of 40 bps[26] YTD 2025 Performance Summary - YTD 2025 global reported sales were $83 billion, a 2% operational growth[24] - Adjusted diluted EPS was $183, a 40% increase[24] - Baxter expects full-year 2025 operational sales growth to be between 1% and 2%[60] - Baxter projects adjusted diluted EPS for full-year 2025 to be between $235 and $240[60]